StockNews.com lowered shares of ADMA Biologics ( NASDAQ:ADMA – Get Rating ) from a hold rating to a sell rating in a research note released on Thursday. A number of other brokerages have also weighed in on ADMA. TheStreet upgraded ADMA Biologics from a d rating to a c- rating in a research report on Friday, May 19th. HC Wainwright reiterated a buy rating and issued a $4.50 price objective on shares of ADMA Biologics in a research report on Wednesday, February 8th. ADMA opened at $4.05 on Thursday.

https://www.dailypolitical.com/2023/06/03/adma-biologics-nasdaqadma-cut-to-sell-at-stocknews-com.html

#dailypolitical